{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:51:24Z","timestamp":1781675484729,"version":"3.54.5"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aMAP score has proven a reliable model for predicting the risk of hepatocellular carcinoma (HCC) development in patients with various types of hepatitis, but its value in predicting recurrence in HCC patients after radiofrequency ablation (RFA) remains unclear. This study aims to assess the utility of the aMAP score for predicting recurrence in HCC patients after RFA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The retrospective analysis included 350 firstly diagnosed HCC patients who underwent RFA. Survival analysis was performed using Kaplan-Meier curves with the log-rank test. Cox regression analysis was conducted to assess the prognostic value of aMAP score. The Fine-Gray method was adopted for sensitivity analysis. Subgroup analyses verified the consistency of the aMAP score\u2019s predictive value. C-index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate its incremental predictive value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 350 patients undergoing RFA, a total of 197 (56.3%) patients had a low aMAP score (\u2264 63.55), and 153 patients (43.7%) had a high aMAP score (&amp;gt; 63.55). Patients with low aMAP scores exhibited significantly longer recurrence-free survival (RFS) (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.016). Multivariate analysis confirmed that the aMAP score is an independent prognostic factor for RFS (\n                      <jats:italic>HR<\/jats:italic>\n                      \u00a0=\u00a01.40,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.028). Furthermore, when incorporated into a tumor-related characteristics model (tumor number and size of largest tumor), the aMAP score provided significant incremental value in predicting RFS (IDI 2.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.036; NRI 15.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.036).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The aMAP score is a potentially predictor for HCC patients undergoing RFA. Incorporation of the aMAP score into the prediction model improved its predictive accuracy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1849758","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:52:34Z","timestamp":1781671954000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The aMAP score improves discrimination of prognostic models in hepatocellular carcinoma after radiofrequency ablation"],"prefix":"10.3389","volume":"16","author":[{"given":"Luchang","family":"Fan","sequence":"first","affiliation":[{"name":"First Central Hospital of Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"First Central Hospital of Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Tianjin Third Central Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Tianjin Third Central Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Tianjin Third Central Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Tianjin First Central Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Cheng","sequence":"additional","affiliation":[{"name":"First Central Hospital of Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Tianjin First Central Hospital","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Central Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Tianjin Third Central Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00500-6","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00967-4","article-title":"Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions","volume":"21","author":"Mak","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29913","article-title":"Diagnosis staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000539349","article-title":"Hepatocellular carcinoma: prevention, diagnosis, and treatment","volume":"33","author":"Feng","year":"2024","journal-title":"Med Princ Pract"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1634\/theoncologist.2018-0337","article-title":"Radiofrequency ablation and microwave ablation in liver tumors: An update","volume":"24","author":"Izzo","year":"2019","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1032746","article-title":"Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2023.05.002","article-title":"Radiofrequency ablation of hepatocellular carcinoma: Current status, challenges, and prospects","volume":"7","author":"Wang","year":"2023","journal-title":"Liv Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8275","DOI":"10.1038\/s41598-021-87782-y","article-title":"A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma","volume":"11","author":"He","year":"2021","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5009\/gnl20101","article-title":"Change in the recurrence pattern and predictors over time after complete cure of hepatocellular carcinoma","volume":"15","author":"Lee","year":"2021","journal-title":"Gut Liv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-10165-6","article-title":"Radiofrequency ablation of subcapsular versus nonsubcapsular hepatocellular carcinomas\u2009\u2264\u20093 cm: Analysis of long-term outcomes from two large-volume liver centers","volume":"34","author":"Han","year":"2024","journal-title":"Eur Radiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000367999","article-title":"Radiofrequency ablation for hepatocellular carcinoma measuring 2 cm or smaller: results and risk factors for local recurrence","volume":"32","author":"Kono","year":"2014","journal-title":"Dig Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2023.2256498","article-title":"A novel prognostic model based on AFP, tumor burden score and Albumin-Bilirubin grade for patients with hepatocellular carcinoma undergoing radiofrequency ablation","volume":"40","author":"Huang","year":"2023","journal-title":"Int J Hyperthermia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317720863","article-title":"Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma","volume":"39","author":"Hong","year":"2017","journal-title":"Tumor Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244167","article-title":"Albumin-bilirubin grade as a valuable predictor of recurrence and prognosis in patients with hepatocellular carcinoma following radiofrequency ablation","volume":"16","author":"Lee","year":"2024","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16051","article-title":"ViT-based quantification of intratumoral heterogeneity for predicting the early recurrence in HCC following multiple ablation","volume":"45","author":"Zhang","year":"2025","journal-title":"Liv Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102381","article-title":"Assessing the predictive accuracy of the aMAP risk score for hepatocellular carcinoma (HCC): Diagnostic test accuracy and meta-analysis","volume":"15","author":"Elgenidy","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01851-1","article-title":"Evaluation of the aMAP score for hepatocellular carcinoma surveillance: A realistic opportunity to risk stratify","volume":"127","author":"Johnson","year":"2022","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7150\/jca.79377","article-title":"The aMAP score is an independent risk factor for intermediate-stage hepatocellular carcinoma: A large retrospective cohort study","volume":"14","author":"Chen","year":"2023","journal-title":"J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2024.01.001","article-title":"The aMAP score predicts long-term outcomes after resection of hepatocellular carcinoma: A multi-institutional analysis","volume":"26","author":"Tsilimigras","year":"2024","journal-title":"HPB"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000530987","article-title":"Usefulness of aMAP risk score for predicting recurrence after curative treatment for hepatocellular carcinoma within milan criteria","volume":"101","author":"Ohama","year":"2023","journal-title":"Oncology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112138-20221108-00835","article-title":"Predictive value of aMAP risk score for early recurrence of small hepatocellular carcinoma after microwave ablation","volume":"62","author":"Dong","year":"2023","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S308587","article-title":"Using the aMAP risk score to predict late recurrence following radiofrequency ablation for hepatocellular carcinoma in chinese population: A multicenter study","volume":"8","author":"Yang","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-21-506","article-title":"Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: A multicenter study","volume":"12","author":"Xin","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"Pinato","year":"2017","journal-title":"J Hepatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100557","article-title":"The ALBI score: From liver function in patients with HCC to a general measure of liver function","volume":"4","author":"Toyoda","year":"2022","journal-title":"JHEP Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.037","article-title":"Validating the ALBI grade: Its current and future use in HCC prognostication","volume":"66","author":"Chan","year":"2017","journal-title":"J Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i18.3228","article-title":"Platelets in liver disease, cancer and regeneration","volume":"23","author":"Kurokawa","year":"2017","journal-title":"World J Gastroenterol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017010868","article-title":"Platelet TGF-\u03b21 deficiency decreases liver fibrosis in a mouse model of liver injury","volume":"2","author":"Ghafoory","year":"2018","journal-title":"Blood Adv"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051243","article-title":"Platelet interactions with liver sinusoidal endothelial cells and hepatic stellate cells lead to hepatocyte proliferation","volume":"9","author":"Meyer","year":"2020","journal-title":"Cells"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14131325","article-title":"Clinical utility of the aMAP score for predicting hepatocellular carcinoma development in patients with chronic hepatitis B","volume":"14","author":"Chaiwiriyawong","year":"2024","journal-title":"Diagnostics"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.677920","article-title":"External validation of aMAP hepatocellular carcinoma risk score in patients with chronic hepatitis B-related cirrhosis receiving ETV or TDF therapy","volume":"8","author":"Gui","year":"2021","journal-title":"Front Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13689","article-title":"aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C","volume":"51","author":"Yamashita","year":"2021","journal-title":"Hepatol Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"S1542","DOI":"10.1016\/j.cgh.2025.09.039","article-title":"Enhanced prediction of hepatitis B virus-related hepatocellular carcinoma using age-male-albumin-bilirubin-platelet (aMAP) and liver stiffness assessed by vibration-controlled transient elastography","volume":"22","author":"Chon","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1016\/j.cgh.2023.03.005","article-title":"aMAP score and its combination with liver stiffness measurement accurately assess liver fibrosis in chronic hepatitis B patients","volume":"21","author":"Fan","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S343457","article-title":"aMAP score as a predictor for long-term outcomes in patients with HBV-related acute-on-chronic liver failure","volume":"15","author":"Sun","year":"2022","journal-title":"Int J Gen Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-018-3810-1","article-title":"Combined preoperative ALBI and FIB-4 is associated with recurrence of hepatocellular carcinoma after curative hepatectomy","volume":"22","author":"Liao","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101568","article-title":"Platelets and hepatocellular cancer: Bridging the bench to the clinics","volume":"11","author":"Lai","year":"2019","journal-title":"Cancers"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11317","article-title":"Relationship between platelet-based models and the prognosis of patients with Malignant hepatic tumors","volume":"19","author":"Hu","year":"2020","journal-title":"Oncol Lett"},{"key":"B43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12964-023-01091-7","article-title":"Insights into the impact of hepatitis B virus on hepatic stellate cell activation","volume":"21","author":"You","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1849758\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:52:39Z","timestamp":1781671959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1849758\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1849758"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1849758","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1849758"}}